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Cystic ﬁbrosis (CF) is a genetic disease rather than an infec-
tious syndrome. It is a severe autosomal recessive illness
affecting Caucasian people as a result of mutations in the CF
transmembrane conductance regulator (CFTR) gene located
on the chromosome 7q31.2 [1,2]. These mutations (of which
more than 1600 have been sequenced) have been classiﬁed
into ﬁve categories (Class I–V) according to the CFTR pro-
tein produced and the phenotypic expression of the disease
[3]. Class I, II and III mutations are associated with severe
pulmonary disease and also with high morbidity and mortality
[4]. Considering the phenotype, some of these mutations,
including the most prevalent (DF508) that accounts for 70%
of CF patients, mainly cause abnormal functioning of mucous
clearance in the lungs, thereby facilitating chronic broncho-
pulmonary colonization, whereas others cause more severe
gastrointestinal and/or hepatic manifestations [2]. Environ-
mental factors have also been identiﬁed that affect the differ-
ential progress of the disease among CF patients [5].
Chronic broncho-pulmonary pathogenic colonization, mainly
due to mucoid Pseudomonas aeruginosa, and progressive dete-
rioration of lung function are the most common respiratory
symptoms in CF patients. These ﬁndings are associated with
a complex course of the disease that is not yet completely
understood.
Mutations in the CFTR gene cause deregulation of sodium
and chloride ion transport and subsequent dehydration of
the airway surface liquid in the lungs and the respiratory
tree, thus producing a viscous mucus layer that cannot be
easily evacuated [6]. A simplistic interpretation of the pulmo-
nary manifestations in CF patients suggested inefﬁciency of
the mucociliary system in the clearance of the microorgan-
isms progressing in the lower respiratory tract. However, a
more complex process might be present.
The airway surface is covered with a thin liquid ﬁlm that
plays a critical role in effective mucociliary clearance [7]. This
liquid is also involved in trapping and removing the inhaled
pathogens without triggering a substantial innate immune
response [8]. In the lungs of CF patients, this ﬁlm is thinner
than under normal conditions and dehydrates as a result of
the deﬁcient CFTR function. Consequently, this results in
the secretion of a thicker mucus than in normal individuals
and a drastic decrease in the clearance. Both features facili-
tate the chronic bacterial colonization/infection, and they
also impede the natural innate immune response.
Moreover, impaired activity of surfactant proteins and of
natural peptides with antimicrobial action at the local level,
such as defensins, has been identiﬁed [6,9].
In recent years, important advances have been made with
respect to the understanding of the inﬂammatory alterations
that occur at the local broncho-pulmonary level [6]. The par-
ticipation of speciﬁc pathogen-associated molecular struc-
tures has also been identiﬁed. They are recognized by
eucariotic speciﬁc receptors (Toll-like receptors; TLR) that
are situated on the surface of the cells of the airway epithe-
lium. This process results in an inﬂammatory response,
including the production of pro-inﬂammatory cytokines that
are responsible for the recruitment of leucocytes and mono-
cytes [5]. In humans, twelve TLRs have been identiﬁed, all of
them with a signiﬁcant role in innate immune responses [10].
Each TLR recognizes and discriminates a speciﬁc bacterial
target. TLR1, TLR2 and TLR6 have been associated with rec-
ognition of cell wall components of Gram-positive bacteria
(i.e. lipoproteins, peptidoglycan and lipoteichoic acid),
whereas TLR4 and TLR5 recognize Gram-negative epitopes
(i.e. lipopolysaccharide and ﬂagellin). The identiﬁcation of
speciﬁc receptors for different pathogens presents a clear
opportunity for exploring new strategies aiming to control
bacterial colonization.
The coexistence of different microorganisms such as
Staphylococcus aureus and P. aeruginosa, or even Candida albi-
cans, is a common feature in CF patients, and may over-stim-
ulate the immune system through different pathways.
Activation of any of the TLRs results in an innate immune
response, which is characterized by nuclear factor-jB activa-
tion and the release of pro-inﬂammatory mediators. Cyto-
kines and chemokines such as interleukin (IL)-8, tumour
necrosis factor (TNF)-a and IL-6 alert the immune system
about the presence of infection, up-regulate antimicrobial
peptide production and increase phagocytosis of bacteria [5].
Particular variants of IL-8 have been associated with a differ-
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ent severity of the lung disease in DF508 homozygous
patients [11]. Nevertheless, immune alterations in the
heterozygous patients or in patients with less common muta-
tions remain unknown but could resemble those observed in
patients with chronic obstructive pulmonary disease or with
non-CF bronchiectasis [12,13].
The immunoglobulin-related transmembrane receptor
termed triggering-receptor expressed on myeloid cells
(TREM-1) is an important element of the innate immune
response [14]. TREM-1 is mainly expressed on monocytes
and neutrophils and its activation occurs after bacterial rec-
ognition, making it a valuable marker of infection in sepsis
[15]. It has been documented that CF patients have a pro-
inﬂammatory status, even in the absence of bacterial coloni-
zation. Defects in the IL-8 secretion, as well as insufﬁcient
neutrophil activation, play an important role in the basal
inﬂammation process [16,17]. The insult produced by viruses
or bacteria triggers and misbalances the innate immune
response. Recently, del Fresno et al. [18] described CF
patients with a low-level production of two critical pro-
inﬂammatory cytokines, TNF-a and IL-6, after bacterial chal-
lenge. They also demonstrated that circulating monocytes
exhibit signiﬁcantly decreased basal levels of TREM-1 and an
endotoxin tolerance state that could modulate the immune
response. This can also provide an opportunity for interven-
tion strategies.
As in patients with chronic obstructive pulmonary disease
or bronchiectasis, inﬂammation and bacterial infection are at
the origin of a vicious circle in CF patients causing tissular
damage in the lung.
Inﬂammation represents a basal status already present at
birth that may facilitate bacterial colonization. Clinical con-
trol and avoidance of the bacterial colonization of the
respiratory tract clearly correlate with a higher quality of
life, as well as an increase in patient survival. Different stud-
ies have documented a high persistence of the same genetic
bacterial lineage in the airway for many years [19,20]. This
means that both the immune system and bacteria, far from
being engaged in an ‘acute’ battle, suffer an attenuation pro-
cess that allows their coexistence. This equilibrium is inter-
rupted during acute respiratory exacerbations and has been
associated with a strong increase in bacterial density.
Although current antibiotic treatments might restore such
equilibrium, they fail to eradicate the microorganism once
chronic colonization is present. Nevertheless, acute sepsis
processes in CF patients are exceptional, which demon-
strates that the immune system, although with some deﬁ-
ciencies, still plays an important role in bacterial
containment. Again, this has been associated with CFTR
alterations in CF patients because this protein has also
been identiﬁed as a key receptor for bacterial internaliza-
tion [21].
In addition to the impaired inﬂammatory response, a par-
ticular niche for the persistence of microorganisms is pro-
duced in the lung in CF patients. The bronchial mucosa is an
adequate platform for microorganisms to grow, nutrients are
easily obtained and temperatures, as well as the atmosphere,
are satisfactory for CF pathogens. In this context, it was
recently demonstrated that anaerobic conditions are present
in the bronchial mucosa of CF patients, facilitating the pro-
duction of alginate and bioﬁlm formation [22]. The latter,
also termed the sessile mode of growth, should be recog-
nized as representing the natural mode of growth of P. aeru-
ginosa in the lung rather than planktonic growth. This should
be also considered in the design of antibiotic therapy
because oxygen limitation increases antibiotic tolerance and
contributes to the persistence of bacterial pathogens [22,23].
In P. aeruginosa, adaptation and persistence are easily pro-
duced under microaerobic respiration [24]. Tenacity and the
particular environmental conditions facilitating hypermutabili-
ty also provide opportunities for pathogens to adapt and to
attenuate the immune host response [25]. Hypermutability,
as reviewed by Oliver and Mena [26] in this theme section,
not only contributes to antimicrobial resistance, but also
to the evolution of virulence, genetic adaptation to the air-
ways of CF patients and the persistence of colonization and
transmissibility.
With respect to these processes, the clinical microbiology
laboratory has contributed to the understanding of the path-
ogenic broncho-pulmonary colonization of CF patients, in
particular by addressing the infection proﬁle during exarcer-
bations and chronic colonization.
Moreover, the recent introduction of molecular and mass
spectrometric (i.e. matrix-assisted laser desorption/ionization
time-of-ﬂight) techniques has facilitated this understanding
and the identiﬁcation of potential new bacterial and fungal
pathogens [27]. Recently, metagenomic approaches in the
study of respiratory secretions of CF patients have also con-
tributed to the recognition of new pathogens, including
viruses, as well as their potential interplay with classical CF
pathogens [28–30]. This speciﬁc topic is reviewed by Bittar
and Rolain [31] in this theme section.
Pathogenic colonization of the broncho-pulmonary com-
partment in CF patients has been deﬁned as the persis-
tence of microorganisms without tissue invasion but
causing local injury [32]. The identiﬁcation of microorgan-
isms responsible for this process comprises an important
routine task for clinical microbiology laboratories, which
thereby contributes to an understanding of the progression
of the disease and to the pharmacological management of
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these patients [33]. Bacterial cultures of respiratory sam-
ples, mainly expectorated sputum, are routinely performed
in clinical laboratories. This includes the identiﬁcation of
major pathogens in the pulmonary secretions that are asso-
ciated with exacerbations of CF and deterioration of pul-
monary function [34].
At an early age in CF patients, infections as a result of
common respiratory pathogens are present, including Strepto-
coccus pneumoniae, Haemophilus inﬂuenzae and S. aureus.
Other pathogens, such as P. aeruginosa, Stenotrophomonas
maltophilia, Burkholderia cepacia, Achromobacter xyloxosidans
and other, less frequent, nonfermentative Gram-negative bac-
teria, appear as late colonizers [28,34]. Among them, P. aeru-
ginosa has clear implications with respect to lung
deterioration and extensive research efforts have been
directed toward this pathogen and an understanding of its
interaction with the lungs [21]. Nevertheless, other patho-
gens, such as Burkholderia cenocepacia, a species within the
B. cepacia complex, have gained notoriety among CF patients
because they are difﬁcult to identify, cause treatment prob-
lems, are able to spread and are correlated with lung deteri-
oration. The importance of this pathogen is reviewed in this
theme section by Drevinek and Mahenthiralingam [35].
Other pathogens still are also isolated from the sputum of
CF patients, including non-Mycobacterium tuberculosis myco-
bacteria, anaerobes and Pneumocystis jiroveci [36–39].
Also, certain fungal pathogens are commonly present in
CF respiratory samples, although their role in pulmonary
damage remains unknown. Although the clinical relevance
of airway colonization with these organisms is still a matter
of debate, they may contribute to the local inﬂammatory
response, and therefore to the progressive deterioration of
the lung. Interference of commensalism with other patho-
gens cannot be ruled out. In the case of anaerobes, which
are not routinely searched for in respiratory samples, an
increased bacterial load along with resistance to antimicro-
bial agents commonly used in CF patients has been
observed [38,39].
Co-colonization by various microorganisms is common in
CF patients and, in addition to the over-stimulation of the
immune system, the interaction among them must be taken
into account. For example, it has been demonstrated that,
when S. aureus grows in the presence of the P. aeruginosa
exoproduct 4-hydroxy-2-heptylquinoline-N-oxide, the
appearance of small-colony variants (SCVs) is promoted, as
well as a bioﬁlm mode of growth [40,41]. Most of the pub-
lished studies about the inter-relationship between the
immune system and CF microorganisms have been per-
formed using bacteria grown in the planktonic mode,
although the results have been obtained under different
bioﬁlm conditions [42]. Activation of some genes occurs only
under bioﬁlm conditions [43], and a higher production of
TNF-a and IL-6 has been observed in the presence of CF
P. aeruginosa isolates [44].
Another important factor that is usually ignored comprises
the reaction promoted by antibiotics in bacterial cells. Some
antibiotics (e.g. ciproﬂoxacin and quinolones in general) stim-
ulate stress response in the bacteria and could have an inﬂu-
ence with respect to not only the development of resistance,
but also the immune response.
An important issue that has been explored in CF patho-
gens is the importance of bacterial adaptation after initial col-
onization that leads to persistence. Most of these studies
have been performed with P. aeruginosa in which, for the ini-
tial stages, no major differences have been observed among
environmental isolates and those producing colonization in
CF patients [45]. However, during the progression of the
disease, the attenuation of virulence determinants and adap-
tive mutational processes, as facilitated by hypermutation and
physiological adaptation, and mainly the adoption of a bioﬁlm
mode of growth, have been recognized to inﬂuence this
process [46].
It is assumed that once bacterial colonization is estab-
lished, the opportunity for bacterial eradication decreases,
whereas the probability for persistence increases. After colo-
nization, speciﬁc virulence factors are triggered, such as algi-
nate production, the formation of SCVs, the emergence of
non-motile subtypes, and the expression of LPS-deﬁcient
variants, as well as the formation of auxotrophic variants.
For example, non-motile variants of P. aeruginosa are fre-
quently recognized among chronically colonized patients and
they are also associated with bioﬁlm formation, as well as
being particularly represented in SCVs that are normally
recovered from patients with advanced chronic colonization
[47].
To insure extended colonization, CF pathogens must
undergo an attenuation process that minimizes their viru-
lence and avoids stimulating the host immune system. Differ-
ent studies have shown that long-term colonization of the
airways in CF patients is associated with extensive genetic
adaptation of P. aeruginosa, despite clonal stability [48,49].
This process is catalyzed by hypermutation and is conducted
to preserve the chronic stage [25]. Nevertheless, epigenetic
modulation may inﬂuence long-term persistence, producing
an equilibrium between potential bacterial injury and the
immune response. It has been recently shown that P. aerugin-
osa, and particularly the mucoid strains, do not lose their
epigenetic regulation of virulence traits such as quorum sens-
ing (or the ability to produce rhamnolipids) until the late
stage of chronic colonization [50].
CMI Canto´n and del Campo Cystic ﬁbrosis: deciphering the complexity 795
ª2010 The Authors
Journal Compilation ª2010 European Society of Clinical Microbiology and Infectious Diseases, CMI, 16, 793–797
Finally, other alternatives to assure extended colonization
could comprise continuous changes in bacterial surfaces,
whereby TLRs would be avoided with consequent escape
from the innate inmuno response.
This possibility has recently been demonstrated for methi-
cillin-resistant S. aureus [42]. A single ST247-SCCmecI-MRSA
clone presenting six different spa-types was detected in a
period of 13 years in the sputum of a CF patient. The bacte-
rial adaptations in patients such as this may shift the
response of the monocytes from the classical to an alterna-
tive or attenuated response.
In conclusion, complex parallel processes occur in bacte-
rial pathogens colonizing the broncho-pulmonary compart-
ment, as well as in the corresponding innate immune defence
in CF patients, with multilevel and transversal interference.
An understanding of these processes is beneﬁcial for the
management of these patients and should provide opportuni-
ties for the design of new treatment strategies.
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